Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India.
Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.
Endocr Pract. 2022 Feb;28(2):191-198. doi: 10.1016/j.eprac.2021.12.009. Epub 2021 Dec 14.
Data for the association between diabetes and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) susceptibility are conflicting. We aimed to evaluate this association using an analytical cross-sectional study design.
Study participants were recruited from endocrine clinics of our hospital and belonged to 3 groups: group 1 (type 1 diabetes mellitus [T1DM]), group 2 (type 2 diabetes mellitus [T2DM]), and group 3 (controls). All participants submitted blood samples for SARS-CoV-2 S1/S2 immunoglobulin G antibody test (LIAISON; DiaSorin) and were interviewed for a history of documented infection.
We evaluated a total of 643 participants (T1DM, 149; T2DM, 160; control, 334; mean age, 37.9 ± 11.5 years). A total of 324 (50.4%) participants were seropositive for SARS-CoV-2. The seropositivity rate was significantly higher in the T1DM (55.7% vs 44.9%, P = .028) and T2DM (56.9% vs 44.9%, P = .013) groups than in the control group. The antibody levels in seropositive participants with T1DM and T2DM were not significantly different from those in seropositive controls. On multivariable analysis, low education status (odds ratio [OR], 1.41 [95% CI, 1.03-1.94]; P = .035), diabetes (OR, 1.68 [95% CI, 1.20-2.34]; P = .002), and overweight/obesity (OR, 1.52 [95% CI, 1.10-2.10]; P = .012) showed a significant association with SARS-CoV-2 seropositivity. The association between diabetes and SARS-CoV-2 seropositivity was found to further increase in participants with coexisting overweight/obesity (adjusted OR, 2.63 [95% CI, 1.54-4.47]; P < .001).
SARS-CoV-2 seropositivity, assessed before the onset of the national vaccination program, was significantly higher in participants with T1DM and T2DM than in controls. The antibody response did not differ between seropositive participants with and without diabetes. These findings point toward an increased SARS-CoV-2 susceptibility for patients with diabetes, in general, without any differential effect of the diabetes type.
关于糖尿病与严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)易感性之间的关联,现有数据相互矛盾。本研究旨在通过分析性横断面研究设计来评估这种关联。
研究参与者从我院内分泌科招募,分为 3 组:第 1 组(1 型糖尿病[T1DM])、第 2 组(2 型糖尿病[T2DM])和第 3 组(对照组)。所有参与者均提交 SARS-CoV-2 S1/S2 免疫球蛋白 G 抗体检测(LIAISON;DiaSorin)的血样,并接受有记录的感染史访谈。
本研究共评估了 643 名参与者(T1DM:149 名;T2DM:160 名;对照组:334 名;平均年龄 37.9±11.5 岁)。共有 324 名(50.4%)参与者 SARS-CoV-2 血清抗体呈阳性。T1DM 组(55.7%比 44.9%,P=0.028)和 T2DM 组(56.9%比 44.9%,P=0.013)的血清阳性率明显高于对照组。T1DM 和 T2DM 血清抗体阳性参与者的抗体水平与血清抗体阳性对照组无显著差异。多变量分析显示,低教育程度(比值比[OR],1.41[95%可信区间,1.03-1.94];P=0.035)、糖尿病(OR,1.68[95%可信区间,1.20-2.34];P=0.002)和超重/肥胖(OR,1.52[95%可信区间,1.10-2.10];P=0.012)与 SARS-CoV-2 血清阳性显著相关。糖尿病与 SARS-CoV-2 血清阳性的相关性在同时存在超重/肥胖的参与者中进一步增加(校正比值比[OR],2.63[95%可信区间,1.54-4.47];P<0.001)。
在全国疫苗接种计划实施之前,与对照组相比,T1DM 和 T2DM 参与者的 SARS-CoV-2 血清阳性率明显更高。血清抗体阳性的参与者与无糖尿病的参与者之间的抗体反应没有差异。这些发现表明,糖尿病患者总体上 SARS-CoV-2 的易感性增加,而糖尿病类型无任何差异影响。